Skip to main content
SpringerLink
Log in

The Role of PET/CT in Melanoma Patients: A Surgeon’s Perspective

  • Chapter
  • First Online:
PET/CT and PET/MR in Melanoma and Sarcoma

  • 408 Accesses

Abstract

Surgeons depend upon radiologic imaging for staging melanoma patients, determining resectability of metastases, and surveillance of metastatic melanoma survivors. The combination of functional glucose imaging with fluorodeoxyglucose [18F]-positron emission tomography, FDG PET, with computed tomography (CT) has improved all of these. FDG PET/CT is the most accurate staging study for metastatic melanoma patients, allows for accurate preoperative planning prior to a metastasectomy, and is the most accurate surveillance modality for the metastatic melanoma patients.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 159.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Gritters LS, Francis IR, Zasadny KR, Wahl RL. Initial assessment of positron emission tomography using 2-fluorine-18-fluoro-2-deoxy-D-glucose in the imaging of malignant melanoma. J Nucl Med. 1993;34(9):1420–7.

    CAS  PubMed  Google Scholar 

  2. Gambhir SS. Molecular imaging of cancer with positron emission tomography. Nat Rev Cancer. 2002;2(9):683–93.

    Article  CAS  PubMed  Google Scholar 

  3. Wasif N, Etzioni D, Haddad D, Gray RJ, Bagaria SP, Pockaj BA. Staging studies for cutaneous melanoma in the United States: a population-based analysis. Ann Surg Oncol. 2015;22(4):1366–70.

    Article  PubMed  Google Scholar 

  4. Tchernev G, Popova LV. PET scan misses cutaneous melanoma metastasis with significant tumour size and tumour thickness. Open Access Maced J Med Sci. 2017;5(7):963–6.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Keu KV, Iagaru AH. The clinical use of PET/CT in the evaluation of melanoma. Methods Mol Biol. 2014;1102:553–80.

    Article  CAS  PubMed  Google Scholar 

  6. Koskivuo I, Kemppainen J, Giordano S, Seppanen M, Verajankorva E, Vihinen P, et al. Whole body PET/CT in the follow-up of asymptomatic patients with stage IIB-IIIB cutaneous melanoma(). Acta Oncol. 2016;55(11):1355–9.

    Article  CAS  PubMed  Google Scholar 

  7. Townsend DW, Beyer T. A combined PET/CT scanner: the path to true image fusion. Br J Radiol. 2002;75:S24–30.

    Article  PubMed  Google Scholar 

  8. James ML, Gambhir SS. A molecular imaging primer: modalities, imaging agents, and applications. Physiol Rev. 2012;92(2):897–965.

    Article  CAS  PubMed  Google Scholar 

  9. Bronstein Y, Ng CS, Rohren E, Ross MI, Lee JE, Cormier J, et al. PET/CT in the management of patients with stage IIIC and IV metastatic melanoma considered candidates for surgery: evaluation of the additive value after conventional imaging. AJR Am J Roentgenol. 2012;198(4):902–8.

    Article  PubMed  Google Scholar 

  10. Bastiaannet E, Uyl-de Groot CA, Brouwers AH, van der Jagt EJ, Hoekstra OS, Oyen W, et al. Cost-effectiveness of adding FDG-PET or CT to the diagnostic work-up of patients with stage III melanoma. Ann Surg. 2012;255(4):771–6.

    Article  PubMed  Google Scholar 

  11. Xing Y, Bronstein Y, Ross MI, Askew RL, Lee JE, Gershenwald JE, et al. Contemporary diagnostic imaging modalities for the staging and surveillance of melanoma patients: a meta-analysis. J Natl Cancer Inst. 2011;103(2):129–42.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Howard JH, Thompson JF, Mozzillo N, Nieweg OE, Hoekstra HJ, Roses DF, et al. Metastasectomy for distant metastatic melanoma: analysis of data from the first multicenter selective lymphadenectomy trial (MSLT-I). Ann Surg Oncol. 2012;19(8):2547–55.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Bastiaannet E, Wobbes T, Hoekstra OS, van der Jagt EJ, Brouwers AH, Koelemij R, et al. Prospective comparison of [18F]fluorodeoxyglucose positron emission tomography and computed tomography in patients with melanoma with palpable lymph node metastases: diagnostic accuracy and impact on treatment. J Clin Oncol. 2009;27(28):4774–80.

    Article  PubMed  Google Scholar 

  14. Gulec SA, Faries MB, Lee CC, Kirgan D, Glass C, Morton DL, et al. The role of fluorine-18 deoxyglucose positron emission tomography in the management of patients with metastatic melanoma: impact on surgical decision making. Clin Nucl Med. 2003;28(12):961–5.

    Article  PubMed  Google Scholar 

  15. Crippa F, Leutner M, Belli F, Gallino F, Greco M, Pilotti S, et al. Which kinds of lymph node metastases can FDG PET detect? A clinical study in melanoma. J Nucl Med. 2000;41(9):1491–4.

    CAS  PubMed  Google Scholar 

  16. Damian DL, Fulham MJ, Thompson E, Thompson JF. Positron emission tomography in the detection and management of metastatic melanoma. Melanoma Res. 1996;6(4):325–9.

    Article  CAS  PubMed  Google Scholar 

  17. Webb HR, Latifi HR, Griffeth LK. Utility of whole-body (head-to-toe) PET/CT in the evaluation of melanoma and sarcoma patients. Nucl Med Commun. 2018;39(1):68–73.

    Article  PubMed  Google Scholar 

  18. Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL, et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2017;377(14):1345–56.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Hodi FS, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Cowey CL, et al. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. Lancet Oncol. 2018;19(11):1480–92.

    Article  CAS  PubMed  Google Scholar 

  20. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD, et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2019;381(16):1535–46.

    Article  CAS  PubMed  Google Scholar 

  21. Danielsen M, Kjaer A, Wu M, Martineau L, Nosrati M, Leong SP, et al. Prediction of positron emission tomography/computed tomography (PET/CT) positivity in patients with high-risk primary melanoma. Am J Nucl Med Mol Imaging. 2016;6(5):277–85.

    PubMed  PubMed Central  Google Scholar 

  22. Schule SC, Eigentler TK, Garbe C, la Fougere C, Nikolaou K, Pfannenberg C. Influence of (18)F-FDG PET/CT on therapy management in patients with stage III/IV malignant melanoma. Eur J Nucl Med Mol Imaging. 2016;43(3):482–8.

    Article  PubMed  CAS  Google Scholar 

  23. Niederkohr RD, Rosenberg J, Shabo G, Quon A. Clinical value of including the head and lower extremities in 18F-FDG PET/CT imaging for patients with malignant melanoma. Nucl Med Commun. 2007;28(9):688–95.

    Article  PubMed  Google Scholar 

  24. Frary EC, Gad D, Bastholt L, Hess S. The role of FDG-PET/CT in preoperative staging of sentinel lymph node biopsy-positive melanoma patients. EJNMMI Res. 2016;6(1):73.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  25. Scheier BY, Lao CD, Kidwell KM, Redman BG. Use of preoperative PET/CT staging in sentinel lymph node-positive melanoma. JAMA Oncol. 2016;2(1):136–7.

    Article  PubMed  Google Scholar 

  26. Wagner T, Meyer N, Zerdoud S, Julian A, Chevreau C, Payoux P, et al. Fluorodeoxyglucose positron emission tomography fails to detect distant metastases at initial staging of melanoma patients with metastatic involvement of sentinel lymph node. Br J Dermatol. 2011;164(6):1235–40.

    Article  CAS  PubMed  Google Scholar 

  27. Barsky M, Cherkassky L, Vezeridis M, Miner TJ. The role of preoperative positron emission tomography/computed tomography (PET/CT) in patients with high-risk melanoma. J Surg Oncol. 2014;109(7):726–9.

    Article  PubMed  Google Scholar 

  28. Sondak VK, Liu PY, Warneke J. Surgical Resection for Stage IV melanoma: A southwest Oncology Group trial. J Clin Oncol. 2006;24(Sppl):4575.

    Google Scholar 

  29. Morton DL, Mozzillo N, Thompson JF, Kelley MC, Faries M, Wagner J, et al. MMAIT Clinical Trials Group. An international, randomized, phase III trial of bacillus Calmette-Guerin (BCG) plus allogeneic melanoma vaccine (MCV) or placebo after complete resection of melanoma metastatic to regional or distant sites. J Clin Oncol. 2007;25(18_Suppl):8508.

    Article  Google Scholar 

  30. Morton DL, Mozzillo N, Thompson JF, Kashani-Sabet M, Kelley M, Gammon G, editors. MMAIT-IV Clinical Trial Group. Multicenter double-blind phase 3 trial of Canvaxin vs. placebo as post surgical adjuvant in metastatic melanoma. Society of Surgical Oncology 59th Annual Cancer Symposium; San Diego, CA; 2006.

    Google Scholar 

  31. Caudle AS, Ross MI. Metastasectomy for stage IV melanoma: for whom and how much? Surg Oncol Clin N Am. 2011;20(1):133–44.

    Article  PubMed  Google Scholar 

  32. Essner R, Lee JH, Wanek LA, Itakura H, Morton DL. Contemporary surgical treatment of advanced-stage melanoma. Arch Surg. 2004;139(9):961–6; discussion 6–7.

    Article  PubMed  Google Scholar 

  33. Ollila DW, Laks S, Hseuh EC. Surgery for stage IV metastatic melanoma. In: Melanoma: a modern multidisciplinary approach [internet]. Cham: Springer International Publishing; 2018. p. 467–71.

    Chapter  Google Scholar 

  34. Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol. 2014;32(10):1020–30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Ribas A, Hamid O, Daud A, Hodi FS, Wolchok JD, Kefford R, et al. Association of pembrolizumab with tumor response and survival among patients with advanced melanoma. JAMA. 2016;315(15):1600–9.

    Article  CAS  PubMed  Google Scholar 

  37. Long GV, Flaherty KT, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, et al. Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. Ann Oncol. 2017;28(7):1631–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012;367(18):1694–703.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Andtbacka RH, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J, et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol. 2015;33(25):2780–8.

    Article  CAS  PubMed  Google Scholar 

  40. Louie RJ, Perez MC, Jajja MR, Sun J, Collichio F, Delman KA, et al. Real-world outcomes of talimogene laherparepvec therapy: a multi-institutional experience. J Am Coll Surg. 2019;228(4):644–9.

    Article  PubMed  Google Scholar 

  41. Anwar H, Sachpekidis C, Winkler J, Kopp-Schneider A, Haberkorn U, Hassel JC, et al. Absolute number of new lesions on (18)F-FDG PET/CT is more predictive of clinical response than SUV changes in metastatic melanoma patients receiving ipilimumab. Eur J Nucl Med Mol Imaging. 2018;45(3):376–83.

    Article  CAS  PubMed  Google Scholar 

  42. Wong ANM, McArthur GA, Hofman MS, Hicks RJ. The advantages and challenges of using FDG PET/CT for response assessment in melanoma in the era of targeted agents and immunotherapy. Eur J Nucl Med Mol Imaging. 2017;44(Suppl 1):67–77.

    Article  PubMed  Google Scholar 

  43. Ollila DW. Complete metastasectomy in patients with stage IV metastatic melanoma. Lancet Oncol. 2006;7(11):919–24.

    Article  PubMed  Google Scholar 

  44. Feun L, Gutterman J, Burgess M, et al. The natural history of resectable metastatic melanoma (stage IV a melanoma). Cancer. 1982;50:1656–63.

    Article  CAS  PubMed  Google Scholar 

  45. Overett TK, Shiu MH. Surgical treatment of distant metastatic melanoma. Indications and results. Cancer. 1985;56(5):1222–30.

    Article  CAS  PubMed  Google Scholar 

  46. Meyer T, Merkel S, Goehl J, Hohenberger W. Surgical therapy for distant metastases of malignant melanoma. Cancer. 2000;89(9):1983–91.

    Article  CAS  PubMed  Google Scholar 

  47. Markowitz J, Cosimi L, Carey R, et al. Prognosis after initial recurrence of cutaneous melanoma. Ann Surg. 1991;214:70–707.

    Google Scholar 

  48. Karakousis C, Velez A, Driscoll B, et al. Metastasectomy in malignant melanoma. Surgery. 1994;115:295–302.

    CAS  PubMed  Google Scholar 

  49. Gadd M, Coit D. Recurrence patterns and outcome in 1019 patients undergoing axillary or inguinal lymphadenopathy for melanoma. Arch Surg. 1992;127:1412–6.

    Article  CAS  PubMed  Google Scholar 

  50. Harpole DH Jr, Johnson CM, Wolfe WG, George SL, Seigler HF. Analysis of 945 cases of pulmonary metastatic melanoma. J Thorac Cardiovasc Surg. 1992;103(4):743–8; discussion 8–50.

    Article  PubMed  Google Scholar 

  51. Tafra L, Dale PS, Wanek LA, Ramming KP, Morton DL. Resection and adjuvant immunotherapy for melanoma metastatic to the lung and thorax. J Thorac Cardiovasc Surg. 1995;110(1):119–28; discussion 29.

    Article  CAS  PubMed  Google Scholar 

  52. Ollila DW, Gleisner AL, Hsueh EC. Rationale for complete metastasectomy in patients with stage IV metastatic melanoma. J Surg Oncol. 2011;104(4):420–4.

    Article  PubMed  Google Scholar 

  53. Ollila D, Essner R, Wanek L, et al. Surgical resection for melanoma metastatic to the gastrointestinal tract. Arch Surg. 1996;131:975–9.

    Article  CAS  PubMed  Google Scholar 

  54. Ricaniadis N, Konstadoulakis M, Walsh D, et al. Gastrointestinal metastases from malignant melanoma. Surg Oncol. 1995;4:105–10.

    Article  CAS  PubMed  Google Scholar 

  55. Agrawal S, Yao T, Coit D. Surgery for melanoma metastatic to the gastrointestinal tract. Ann Surg Oncol. 1999;6:336–44.

    Article  CAS  PubMed  Google Scholar 

  56. Klaase JM, Kroon BB. Surgery for melanoma metastatic to the gastrointestinal tract. Br J Surg. 1990;77(1):60–1.

    Article  CAS  PubMed  Google Scholar 

  57. Gutman H, Hess K, Kokoysakis J, et al. Surgery for abdominal metastases of cutaneous melanoma. World J Surg. 2001;25:750–8.

    Article  CAS  PubMed  Google Scholar 

  58. Sosman JA, Moon J, Tuthill RJ, Warneke JA, Vetto JT, Redman BG, et al. A phase 2 trial of complete resection for stage IV melanoma: results of Southwest Oncology Group Clinical Trial S9430. Cancer. 2011;117(20):4740–06.

    Article  PubMed  Google Scholar 

  59. Conrad F, Winkens T, Kaatz M, Goetze S, Freesmeyer M. Retrospective chart analysis of incidental findings detected by (18) F-fluorodeoxyglucose-PET/CT in patients with cutaneous malignant melanoma. J Dtsch Dermatol Ges. 2016;14(8):807–16.

    PubMed  Google Scholar 

  60. Bastiaannet E, Oyen WJ, Meijer S, Hoekstra OS, Wobbes T, Jager PL, et al. Impact of [18F]fluorodeoxyglucose positron emission tomography on surgical management of melanoma patients. Br J Surg. 2006;93(2):243–9.

    Article  CAS  PubMed  Google Scholar 

  61. Gershenwald JE, Scolyer RA, Hess KR, Sondak VK, Long GV, Ross MI, et al. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67(6):472–92.

    Article  PubMed  PubMed Central  Google Scholar 

  62. Goel N, Ward WH, Yu JQ, Farma JM. Short-term and long-term management of melanoma. In: Ward WH, Farma JM, editors. Cutaneous melanoma: etiology and therapy. Brisbane: Codon Publications; 2017.

    Google Scholar 

  63. Leon-Ferre RA, Kottschade LA, Block MS, McWilliams RR, Dronca RS, Creagan ET, et al. Association between the use of surveillance PET/CT and the detection of potentially salvageable occult recurrences among patients with resected high-risk melanoma. Melanoma Res. 2017;27(4):335–41.

    Article  PubMed  Google Scholar 

  64. Cust AE, Badcock C, Smith J, Thomas NE, Haydu LE, Armstrong BK, et al. A risk prediction model for development of subsequent primary melanoma in a population-based cohort. Br J Dermatol. 2020;182(5):1148–57.

    Article  CAS  PubMed  Google Scholar 

  65. Romano E, Scordo M, Dusza SW, Coit DG, Chapman PB. Site and timing of first relapse in stage III melanoma patients: implications for follow-up guidelines. J Clin Oncol. 2010;28(18):3042–7.

    Article  PubMed  PubMed Central  Google Scholar 

  66. Garbe C, Paul A, Kohler-Spath H, Ellwanger U, Stroebel W, Schwarz M, et al. Prospective evaluation of a follow-up schedule in cutaneous melanoma patients: recommendations for an effective follow-up strategy. J Clin Oncol. 2003;21(3):520–9.

    Article  PubMed  Google Scholar 

  67. Lewin JH, Sanelli A, Walpole I, Kee D, Henderson MA, Speakman D, et al. Surveillance imaging with FDG-PET in the follow-up of melanoma patients at high risk of relaps. JCO. 2015;20(33(15_suppl)):151–7.

    Google Scholar 

  68. Hofmann U, Szedlak M, Rittgen W, Jung EG, Schadendorf D. Primary staging and follow-up in melanoma patients--monocenter evaluation of methods, costs and patient survival. Br J Cancer. 2002;87(2):151–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. Kurtz J, Beasley GM, Agnese D, Kendra K, Olencki TE, Terando A, et al. Surveillance strategies in the follow-up of melanoma patients: too much or not enough? J Surg Res. 2017;214:32–7.

    Article  PubMed  Google Scholar 

  70. Lewin J, Sayers L, Kee D, Walpole I, Sanelli A, Te Marvelde L, et al. Surveillance imaging with FDG-PET/CT in the post-operative follow-up of stage 3 melanoma. Ann Oncol. 2018;29(7):1569–74.

    Article  CAS  PubMed  Google Scholar 

  71. Vensby PH, Schmidt G, Kjaer A, Fischer BM. The value of FDG PET/CT for follow-up of patients with melanoma: a retrospective analysis. Am J Nucl Med Mol Imaging. 2017;7(6):255–62.

    CAS  PubMed  PubMed Central  Google Scholar 

  72. Wong SL, Faries MB, Kennedy EB, Agarwala SS, Akhurst TJ, Ariyan C, et al. Sentinel lymph node biopsy and management of regional lymph nodes in melanoma: American Society of Clinical Oncology and Society of Surgical Oncology clinical practice guideline update. Ann Surg Oncol. 2018;25(2):356–77.

    Article  PubMed  Google Scholar 

  73. Khan SA, Bank J, Song DH, Choi EA. The skin and subcutaneous tissue. In: Brunicardi FC, Andersen DK, Billiar TR, Dunn DL, Hunter JG, Matthews JB, editors. Schwartz’s principles of surgery [Internet]. 10th ed. New York: McGraw-Hill Education; 2014. Available from: accessmedicine.mhmedical.com/content.aspx?aid=1117743615.

    Google Scholar 

  74. Schaarschmidt BM, Grueneisen J, Stebner V, Klode J, Stoffels I, Umutlu L, et al. Can integrated 18F-FDG PET/MR replace sentinel lymph node resection in malignant melanoma? Eur J Nucl Med Mol Imaging. 2018;45(12):2093–102.

    Article  PubMed  Google Scholar 

  75. Chessa MA, Dika E, Patrizi A, Fanti PA, Piraccini BM, Veronesi G, et al. Sentinel lymph node biopsy versus PET-CT in AJCC stages I and II of melanoma. J Eur Acad Dermatol Venereol. 2017;31(1):e54–e5.

    Article  CAS  PubMed  Google Scholar 

  76. Molina MA, Goodwin WJ, Moffat FL, Serafini AN, Sfakianakis GN, Avisar E. Intra-operative use of PET probe for localization of FDG avid lesions. Cancer Imaging. 2009;9:59–62.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  77. Gulec SA, Daghighian F, Essner R. PET-probe: evaluation of technical performance and clinical utility of a handheld high-energy gamma probe in oncologic surgery. Ann Surg Oncol. 2016;23(Suppl 5):9020–7.

    Article  PubMed  Google Scholar 

  78. Gulec SA, Hoenie E, Hostetter R, Schwartzentruber D. PET probe-guided surgery: applications and clinical protocol. World J Surg Oncol. 2007;5:65.

    Article  PubMed  PubMed Central  Google Scholar 

  79. Franc BL, Mari C, Johnson D, Leong SP. The role of a positron- and high-energy gamma photon probe in intraoperative localization of recurrent melanoma. Clin Nucl Med. 2005;30(12):787–91.

    Article  PubMed  Google Scholar 

  80. Essner R, Hsueh EC, Haigh PI, Glass EC, Huynh Y, Daghighian F. Application of an [(18)F]fluorodeoxyglucose-sensitive probe for the intraoperative detection of malignancy. J Surg Res. 2001;96(1):120–6.

    Article  CAS  PubMed  Google Scholar 

  81. Holder WD Jr, White RL Jr, Zuger JH, Easton EJ Jr, Greene FL. Effectiveness of positron emission tomography for the detection of melanoma metastases. Ann Surg. 1998;227(5):764–9; discussion 9–71.

    Article  PubMed  PubMed Central  Google Scholar 

  82. Rinne D, Baum RP, Hor G, Kaufmann R. Primary staging and follow-up of high risk melanoma patients with whole-body 18F-fluorodeoxyglucose positron emission tomography: results of a prospective study of 100 patients. Cancer. 1998;82(9):1664–71.

    Article  CAS  PubMed  Google Scholar 

  83. Eigtved A, Andersson AP, Dahlstrom K, Rabol A, Jensen M, Holm S, et al. Use of fluorine-18 fluorodeoxyglucose positron emission tomography in the detection of silent metastases from malignant melanoma. Eur J Nucl Med. 2000;27(1):70–5.

    Article  CAS  PubMed  Google Scholar 

  84. Tyler DS, Onaitis M, Kherani A, Hata A, Nicholson E, Keogan M, et al. Positron emission tomography scanning in malignant melanoma. Cancer. 2000;89(5):1019–25.

    Article  CAS  PubMed  Google Scholar 

  85. Fuster D, Chiang S, Johnson G, Schuchter LM, Zhuang H, Alavi A. Is 18F-FDG PET more accurate than standard diagnostic procedures in the detection of suspected recurrent melanoma? J Nucl Med. 2004;45(8):1323–7.

    PubMed  Google Scholar 

  86. Iagaru A, Quon A, Johnson D, Gambhir SS, McDougall IR. 2-Deoxy-2-[F-18]fluoro-D-glucose positron emission tomography/computed tomography in the management of melanoma. Mol Imaging Biol. 2007;9(1):50–7.

    Article  CAS  PubMed  Google Scholar 

  87. Pfannenberg C, Aschoff P, Schanz S, Eschmann SM, Plathow C, Eigentler TK, et al. Prospective comparison of 18F-fluorodeoxyglucose positron emission tomography/computed tomography and whole-body magnetic resonance imaging in staging of advanced malignant melanoma. Eur J Cancer. 2007;43(3):557–64.

    Article  PubMed  Google Scholar 

  88. Peric B, Zagar I, Novakovic S, Zgajnar J, Hocevar M. Role of serum S100B and PET-CT in follow-up of patients with cutaneous melanoma. BMC Cancer. 2011;11:328.

    Article  PubMed  PubMed Central  Google Scholar 

  89. Aukema TS, Valdes Olmos RA, Wouters MW, Klop WM, Kroon BB, Vogel WV, et al. Utility of preoperative 18F-FDG PET/CT and brain MRI in melanoma patients with palpable lymph node metastases. Ann Surg Oncol. 2010;17(10):2773–8.

    Article  PubMed  Google Scholar 

  90. Gellen E, Santha O, Janka E, Juhasz I, Peter Z, Erdei I, et al. Diagnostic accuracy of (18)F-FDG-PET/CT in early and late stages of high-risk cutaneous malignant melanoma. J Eur Acad Dermatol Venereol. 2015;29(10):1938–44.

    Article  CAS  PubMed  Google Scholar 

  91. Chandra P, Purandare N, Shah S, Agrawal A, Puri A, Gulia A, et al. Diagnostic accuracy and impact of fluorodeoxyglucose positron emission tomography/computed tomography in preoperative staging of cutaneous malignant melanoma: results of a prospective study in Indian population. World J Nucl Med. 2017;16(4):286–92.

    Article  PubMed  PubMed Central  Google Scholar 

  92. Stas M, Stroobants S, Dupont P, Gysen M, Hoe LV, Garmyn M, et al. 18-FDG PET scan in the staging of recurrent melanoma: additional value and therapeutic impact. Melanoma Res. 2002;12(5):479–90.

    Article  CAS  PubMed  Google Scholar 

  93. Harris MT, Berlangieri SU, Cebon JS, Davis ID, Scott AM. Impact of 2-deoxy-2[F-18]fluoro-D-glucose positron emission tomography on the management of patients with advanced melanoma. Mol Imaging Biol. 2005;7(4):304–8.

    Article  PubMed  Google Scholar 

  94. Reinhardt MJ, Joe AY, Jaeger U, Huber A, Matthies A, Bucerius J, et al. Diagnostic performance of whole body dual modality 18F-FDG PET/CT imaging for N- and M-staging of malignant melanoma: experience with 250 consecutive patients. J Clin Oncol. 2006;24(7):1178–87.

    Article  PubMed  Google Scholar 

  95. Falk MS, Truitt AK, Coakley FV, Kashani-Sabet M, Hawkins RA, Franc B. Interpretation, accuracy and management implications of FDG PET/CT in cutaneous malignant melanoma. Nucl Med Commun. 2007;28(4):273–80.

    Article  CAS  PubMed  Google Scholar 

  96. Etchebehere EC, Romanato JS, Santos AO, Buzaid AC, Camargo EE. Impact of [F-18] FDG-PET/CT in the restaging and management of patients with malignant melanoma. Nucl Med Commun. 2010;31(11):925–30.

    Article  PubMed  Google Scholar 

  97. Singnurkar A, Wang J, Joshua AM, Langer DL, Metser U. 18F-FDG-PET/CT in the staging and Management of Melanoma: a prospective Multicenter Ontario PET Registry Study. Clin Nucl Med. 2016;41(3):189–93.

    Article  PubMed  Google Scholar 

  98. Forschner A, Olthof SC, Guckel B, Martus P, Vach W, la Fougere C, et al. Impact of (18)F-FDG-PET/CT on surgical management in patients with advanced melanoma: an outcome based analysis. Eur J Nucl Med Mol Imaging. 2017;44(8):1312–8.

    Article  PubMed  Google Scholar 

  99. Pfannenberg C, Gueckel B, Wang L, Gatidis S, Olthof SC, Vach W, et al. Practice-based evidence for the clinical benefit of PET/CT-results of the first oncologic PET/CT registry in Germany. Eur J Nucl Med Mol Imaging. 2019;46(1):54–64.

    Article  PubMed  Google Scholar 

  100. Gold JS, Jaques DP, Busam KJ, Brady MS, Coit DG. Yield and predictors of radiologic studies for identifying distant metastases in melanoma patients with a positive sentinel lymph node biopsy. Ann Surg Oncol. 2007;14(7):2133–40.

    Article  PubMed  Google Scholar 

  101. Constantinidou A, Hofman M, O’Doherty M, Acland KM, Healy C, Harries M. Routine positron emission tomography and positron emission tomography/computed tomography in melanoma staging with positive sentinel node biopsy is of limited benefit. Melanoma Res. 2008;18(1):56–60.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, St. Louis University, St. Louis, MO, USA

    Ea-sle Chang & Eddy C. Hsueh

  2. Department of Surgery, Division of Surgical Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

    David W. Ollila

Authors
  1. Ea-sle Chang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Eddy C. Hsueh
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. David W. Ollila
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David W. Ollila .

Editor information

Editors and Affiliations

  1. Department of Radiology, UNC School of Medicine, Division of Molecular Imaging and Therapeutics (Mit), Chapel Hill, NC, USA

    Amir H. Khandani

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Chang, Es., Hsueh, E.C., Ollila, D.W. (2021). The Role of PET/CT in Melanoma Patients: A Surgeon’s Perspective. In: Khandani, A.H. (eds) PET/CT and PET/MR in Melanoma and Sarcoma. Springer, Cham. https://doi.org/10.1007/978-3-030-60429-5_7

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-60429-5_7

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-60428-8

  • Online ISBN: 978-3-030-60429-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation